The working group is responsible for the routine performance and interpretation of molecular diagnostics specifically for patients with Chronic Myeloid Leukemia (CML). Our tasks include both diagnostic testing and molecular monitoring as part of ongoing CML surveillance, conducted as a reference laboratory accredited by the Deutsche Akkreditierungsstelle (DAkkS). The laboratory is actively involved in national and international clinical trials (e.g., ASC4START) and provides molecular genetic monitoring for Jena-initiated CML studies such as FAsciNation, ARTIST, and ESTIMATION.

Diagnostic analyses are primarily performed using qualitative multiplex PCR, while quantitative real-time PCR is employed to monitor remission status and disease progression. Mutation analyses are carried out using both Sanger sequencing and Next-Generation Sequencing (NGS). Through these advanced molecular genetic techniques, we ensure precise monitoring of CML patients, enable the early detection of relapse, and contribute to personalized and optimized patient care.